Open AccessElectroretinographic Findings in Melanoma-Associated Retinopathy Treated by Intravitreal Dexamethasone Implant
Author(s) -
Abdullah Abou-Samra,
Radouil T Tzekov,
Nicolas A. Yannuzzi,
Ahmad B. Tarabishy
Publication year - 2021
Publication title -
ophthalmic surgery, lasers and imaging retina
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.676
H-Index - 30
eISSN - 2325-8179
pISSN - 2325-8160
DOI - 10.3928/23258160-20210727-09
Subject(s) - medicine , ophthalmology , photopic vision , implant , erg , electroretinography , surgery , retinal
A 63-year-old male with a history of bladder cancer in remission presented with progressive vision loss during a period of 2 years. Slit-lamp and funduscopic examination were unremarkable. Electroretinogram (ERG) revealed an unrecordable scotopic response and a moderately decreased photopic response. Computed tomography of the chest, abdomen, and pelvis showed a new duodenal mass. Subsequent biopsy disclosed malignant melanoma, and a diagnosis of melanoma-associated retinopathy (MAR) was made. The patient was then treated with a dexamethasone intravitreal implant 0.7 mg in his left eye. Two months after the implant, the patient reported a mild symptomatic improvement in his left eye, and ERG testing performed after the implant insertion revealed partial improvement in several scotopic and photopic ERG parameters. Repeat spectral-domain optical coherence tomography disclosed an improvement in retinal thickening. To the best of the authors' knowledge, this is the first report illustrating potential subjective visual improvement, improvement in retinal thickening, and ERG changes following treatment by intravitreal dexamethasone implant for MAR. [ Ophthalmic Surg Lasers Imaging Retina . 2021;52:454-456.] .